MTOR and cancer: This is exemplified by studies that showed that artesunate treatment in cancer models mitigates the Wnt pathway (Geng et al, 2021), the phosphoinositide-3 kinase/protein kinase B/mTOR pathway (Xiao et al, 2020), as well as their downstream targets (Gong et al, 2022; Yin et al, 2020).